Biomaterials: Advancements in Spinal Cord Injury Treatment

Spinal cord injuries (SCIs) represent some of the most severe forms of trauma, often resulting in irreversible loss of motor and sensory function below the site of injury and profoundly diminishing patients’ quality of life. Despite significant advancements in medical science, the development of effective therapies that can restore lost functions and substantially improve outcomes in patients with SCI remains an ongoing challenge. Current therapeutic strategies, including surgical interventions, intensive rehabilitation, and pharmacological treatments, have primarily focused on stabilising the injury and managing secondary complications, such as spasticity, pain, and inflammation. However, these approaches have shown limited success in promoting the repair and regeneration of damaged spinal cord tissues, highlighting the urgent need for innovative treatment modalities. Biomaterials have emerged as promising frontiers in SCI research, offering novel solutions to the inherent challenges posed by SCI. These engineered materials are designed to interact with biological systems in a controlled manner, providing structural support, facilitating cellular growth, and enabling localised delivery of therapeutic agents directly to the injury site. Furthermore, biomaterials can be tailored to modulate immune responses, reduce inflammation, and create an environment conducive to tissue regeneration. Despite their potential, several critical challenges remain, including ensuring biocompatibility, maintaining long-term stability within the body, and overcoming the risks of immune rejection. Moreover, the translation of biomaterial-based therapies from preclinical studies to clinical applications is a complex and demanding process, necessitating extensive research and rigorous validation. This review aims to critically assess advancements in biomaterials for SCI treatment, focusing on their mechanisms of action, challenges in their application, and future directions.